Adoption of the income statement and balance sheet

The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet.

Allocation of the company's profit or loss

The AGM resolved to dispose of the company's results according to the adopted balance sheet, in accordance with the Board's proposal in the annual report with no dividend to be paid for the financial year 2024/2025. 

Discharge of liability for board members and CEO

The AGM resolved to discharge the members of the board of directors and the managing director from liability for the financial year of 2024/2025.

Determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors

The AGM resolved that the board of directors consist of five (5) ordinary board members and no deputy board member and that one auditor is determined, and no deputy auditors.

Determination of fees for members of the board of directors and auditors

The AGM resolved that the board remuneration should amount to 100,000 SEK for Volker Wiederrich, Jan-Mark Edewaard and Karina Kilinski. Additionally, The AGM also resolved that board fees of SEK 1,000,000 shall be paid to Malcolm Allan and SEK 150,000 shall be paid to board member Gösta Lidén.

Furthermore, the AGM resolved that auditors' fees should be paid according to approved invoice in accordance with customary charging standards.

Election of the board of directors and accounting firm or auditor

The AGM resolved that Karina Kilinski, Malcolm Allan, Jan-Mark Edewaard and Gösta Lidén be re-elected as ordinary board members. As Chairman of the Board, Volker Wiederrich was re-elected.

The AGM also resolved that the company's audit firm Örhlings PricewaterhouseCoopers be re-elected as the company auditor until the end of the Annual General Meeting that is held next financial year.

Stockholm in December 2025
ODI Pharma AB (publ)
THE BOARD

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail.
 

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com                                                                                                             

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.